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Abstract High-grade primary brain tumors possessed
poor outcome due to invasiveness. Extracellular matrix
metalloproteinase inducer (EMMPRIN) stimulates peri-
tumoral fibroblasts to secrete matrix metalloproteinase and
promote invasiveness. This study hypothesized that high-
grade brain tumors overexpress EMMPRIN. Analyzing the
public delinked database from the Gene Expression
Omnibus profile, the results showed that the EMMPRIN
mRNA level was higher in WHO grade IV (n = 81) than in
grade III (n = 19, p \ 0.0005) astrocytomas and non-
tumor brain tissue controls (n = 23, p \ 0.00001). The
results of tissue microarray-based immunohistochemical
(IHC) staining revealed that EMMPRIN levels positively
correlated with WHO grades for astrocytomas (p = 0.008)
and meningiomas (p = 0.048). EMMPRIN mRNA levels
in conventional glioma cell lines (n = 36) was not less
than those in glioma primary culture cells (n = 27) and
glioblastoma stem-like cells (n = 12). The GBM8401,
U87MG, and LN229 human glioma cell lines also over-
expressed EMMPRIN. Hematoxylin and eosin, IHC, and
immunofluorescence staining of xenografts confirmed that
high-grade brain tumors overexpressed EMMPRIN. Lastly,
Kaplan–Meier analysis revealed poorer survival in WHO
grade IV (n = 56) than in grade III astrocytomas (n = 21,
by log-rank test; p = 0.0001, 95 % CI: 1.842–3.053).
However, in high-grade astrocytomas, there was no dif-
ference in survival between high and low EMMPRIN
mRNA levels. Thus, this study identified that high-grade
brain tumors overexpress EMMPRIN, which positively
correlates with WHO grades in human astrocytomas and
meningiomas, and suggests that EMMPRIN may be a
therapeutic target of brain tumor.
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Introduction
Astrocytomas and meningiomas are the two most common
primary brain tumors (PBTs) [1]. Proper histologic grading
is a major predictor of therapeutic effect and prognosis in
PBTs [2]. However, the discrepancy between histologic
classification and aggressive behavior in meningiomas is
around 7–20 % [3]. Therefore, the investigation of bio-
markers is very important to bridge the gap. The Gene
Expression Omnibus (GEO) profiles [4, 5] provided public
delinked database for high-throughput investigation of
biomarkers.
Matrix metalloproteinases degrade all of the molecules
of the extracellular matrix (ECM) [6]. Activation of MMPs
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greatly affects cell–matrix interaction, angiogenesis, and
the inflammatory process [7–9]. Extracellular MMP indu-
cer (EMMPRIN), also called CD147 or basigin (BSG), is a
55-kDa molecule expressed on the tumor cell surface that
plays important roles in the up-regulation of peri-tumoral
fibroblasts [10]. EMMPRIN is also an inducer of MMP-1,
MMP-2, and MMP-3 [6, 11]. Recent studies have shown
that ECM degradation may be related to tumor invasion,
progression, and even metastasis [12]. Thus, EMMPRIN
overexpression is seen in many human cancers, including
oral [13], laryngeal [14], esophageal [15], breast [16],
ovarian [17], cervical [18], hepatic [19], kidney [20],
colorectal carcinomas [21], and T cell lymphomas [22].
EMMPRIN on the surface of glioma cells may also
strengthen tumor progression [23, 24], but the possible role
of EMMPRIN in meningiomas remains unknown.
The present study hypothesized that high-grade brain
tumors overexpress EMMPRIN. Using the GEO profiles,
EMMPRIN expressions in PBTs were investigated and
correlated with World Health Organization (WHO) grades
and survival. Immunohistochemical (IHC) staining of tis-
sue microarray and xenografts were used to validate the
database findings. This study posited that a simple strategy
of combined bioinformatics and wet lab approaches can be
used to identify potential biomarkers in human brain
tumors.
Materials and methods
Analyses of functional genomic databases
The EMMPRIN mRNA expression was obtained from the
GDS1962/208677_s_at/BSG database. http://www.ncbi.
nlm.nih.gov/geo/tools/profileGraph.cgi?ID=GDS1962:208
677_s_at. The sample size and WHO grades enrolled in
this GDS1962 dataset was described previously [25]. The
survival data of 77 primary high-grade astrocytomas
(WHO grades III and IV) obtained from the GDS1815
database (http://www.ncbi.nlm.nih.gov/geo/tools/profile
Graph.cgi?ID=GDS1815:208677_s_at) and devoted by
Phillips et al. [26]. The GDS3885 database included 36
panels of conventional glioma cell lines data, 12 panels of
glioma primary culture cells data, and 27 panels of glioma
stem-like cells data (http://www.ncbi.nlm.nih.gov/geo/
tools/profileGraph.cgi?ID=GDS3885:208677_s_at). The
background of cell line was described previously [27].
Construction of tissue microarray
The Institutional Review Board of Tri-Service General
Hospital, National Defense Medical Center approved this
study. Tissue microarray slides were constructed from 103
paraffin-embedded tissues, including 59 cases of meningi-
omas, 41 cases of astrocytomas, and 3 non-neoplastic brain
tissues. For slide construction, one core (2 mm in diameter)
was taken from a selected area of each paraffin-embedded
tumor tissue. Both the tissue microarray scores and the
corresponding paraffin-embedded specimens were uni-
formly stained. Pathologic diagnosis in these cases was
reviewed by at least two experienced pathologists. The
histo-pathologic differentiation of brain tumors was deter-
mined according to the criteria of the WHO classification
of tumor [28]. None of the astrocytomas and meningiomas
included in this study ever received radiotherapy or che-
motherapy before surgery.
Immunohistochemical (IHC) staining
Tissue microarray sections and xenografts were processed
following previous protocol [2], incubated with a poly-
clonal rabbit anti-human EMMPRIN antibody (1:200
diluted in phosphate buffered saline [PBS]; Bioss, Woburn,
MA, USA) for 1 h at room temperature, washed 3 times
(each for 5 min in PBS), incubated with biotin-labeled
secondary immunoglobulin (1:100, DAKO, Glostrup,
Denmark) for 1 h at room temperature, washed 3 times,
and treated with 3-amino-9-ethylcarbazole substrate chro-
mogen (DAKO, Glostrup, Denmark) at room temperature
to visualize peroxidase activity. Sections of poorly differ-
entiated hepatocellular carcinoma tissue (known to stain
positive for EMMPRIN) were used as positive control and
non-neoplastic liver were used as negative control [19].
Assessment of EMMPRIN immuno-staining scores
To evaluate immuno-reactivity and histologic appearance,
all tissue microarray experiments were repeated two times
and the slides were examined and scored by two investi-
gators concurrently. To assess EMMPRIN immuno-stain-
ing scores, the intensity of cytoplasmic and membranous
staining was scored as 0 (absence of staining), 1 (weak
staining), 2 (moderate staining), or 3 (strong staining).
Weak, moderate, and strong cytoplasmic stainings were
identified by microscopy with magnification of 409, 209,
and 109 or 49, respectively [29]. The cut-off value of
EMMPRIN intensity scores was set by the magnification of
objective lens. The percentage of tumor staining was
scored 0 (\5 %), 1 (5–25 %), 2 (25–50 %), 3 (50–75 %),
and 4 (75–100 %). The EMMPRIN immuno-staining
scores of human astrocytomas and meningiomas were
defined by calculating the intensity score and multiplying it
by the corresponding percentage score. EMMPRIN
immuno-staining scores ranged from 0 to 12, including 0,
1, 2, 3, 4, 6, 8, 9, and 12.
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Cell lysate preparation and Western blots
GBM8401, U87MG, LN229, and HepG2 were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) con-
taining 10 % fetal bovine serum (FBS), penicillin, and
streptomycin. Cell lysates prepared from 2 9 107
GBM8401, U87MG, LN229 glioma cells, and HepG2
hepatoma cell line (positive control) were used for Western
blot analysis of EMMPRIN, with a-actin (Santa Cruz) as
internal control following previous protocol [30].
In vivo orthotopic xenograft
The Institutional Animal Care and Use Committee of
National Defense Medical Center, Taipei, Taiwan
(IACUC-13-147) approved the study of xenografts. The
experimental procedures of in vivo orthotopic xenograft
were as described previously [25, 30–32]. Briefly, 5 9 105
cells were injected into the right cerebral hemisphere of
BALB/cAnN.Cg-Foxn1nu/CrlNarl nude mice. Gliomas
were permitted to grow in the murine brain.
Immunofluorescence (IF) staining
After deparaffinization and rehydration, the tumor samples
were rinsed with PBS. For antigen retrieval, the samples
were heated by a microwave oven in citrate buffer (10 mM
Citric Acid, pH 6.0) for 15 min. After cooling for 15 min,
blocking solution (5 % non-fat milk in 0.1 % Triton
X-100) was applied to block non-specific binding at room
temperature for 30 min. Then, primary antibody (EMM-
PRIN) dissolved in PBS with 5 % non-fat milk was added
to the samples at 4 C overnight. The next day, the samples
were rinsed with PBS and secondary antibody-conjugated
FITC and DAPI (Sigma) were applied at room temperature
for 1 h and 15 min, respectively. The samples were
mounted (Gel mount Aqueous, Sigma) and the slides were
examined by microscopy and photographed (Leica).
Statistical analysis
All results were expressed as mean ± standard deviation
(SD).The correlations between variables of immuno-
staining scores were calculated by the Pearson Product
Moment Method. Student’s two-tailed t test was used to
determine differences in means between any two groups in
EMMPRIN mRNA levels of different WHO grades of
human astrocytoma samples. SigmaState software (Jandel
Scientific, USA) was also used to perform linear regression
testing to analyze the relationships between EMMPRIN
expression and WHO grades of astrocytomas and menin-
giomas. Survival cures were analyzed using the Kaplan–
Meier method, while differences in survival distributions
were investigated by log-rank test. Statistical significance
was set at p \ 0.05.
Results
GEO identified the candidate biomarker EMMPRIN
mRNA level and correlated it with WHO grades
in human astrocytomas
The GDS1962 dataset and statistical analyses were used to
investigate the correlation between EMMPRIN mRNA and
WHO grades (Fig. 1a). In samples with different patho-
logic grades, EMMPRIN mRNA level was higher in WHO
grade IV (n = 81) than in grade III (n = 19) (p \ 0.0005)
human astrocytomas and non-tumor brain tissue controls
(n = 23) (p \ 0.00001, Student’s t test).
Tissue microarray provided the platform to identify
EMMPRIN and correlate with WHO grades in human
astrocytomas
Only weak stain and limited percentage of non-neoplastic
brain tissues were expressed by the IHC staining of EMM-
PRIN (average immuno-staining scores, 0.5 ± 0.4). Com-
pared to non-neoplastic brain tissues, most astrocytomas had
significantly higher expressions of EMMPRIN. Moreover,
the IHC staining intensity and average percentage of tumor
staining in anaplastic astrocytomas (average score, 7.3 ±
3.0) and glioblastoma multiforme (average score, 7.8 ± 2.1)
were higher than in pilocytic astrocytomas (average score,
1.5 ± 0.5) and diffuse astrocytomas (average score, 2.0 ±
1.3). Increased EMMPRIN expression positively correlated
with WHO grade of astrocytomas (p = 0.008) (Fig. 1a, b,
d–k; Table 1).
Tissue microarray provided the platform to identify
EMMPRIN and correlate with WHO grades in human
meningiomas
The IHC staining intensity, percentage of meningioma
expression, and total immuno-staining scores of EMM-
PRIN were shown in Table 1. Most meningiomas showed
higher EMMPRIN immuno-staining scores compared to
non-tumor brain tissues. Furthermore, the intensity and
immuno-staining scores of EMMPRIN in atypical menin-
giomas (5.0 ± 1.8) and anaplastic meningiomas (6.6 ±
3.1) were higher than that of meningothelial meningiomas
(1.3 ± 0.6). The immuno-staining scores of EMMPRIN
significantly correlated with WHO grades of meningiomas
(p = 0.048) (Fig. 1c, l–s; Table 1).
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Fig. 1 Expression of EMMPRIN in human astrocytomas and
meningiomas. a EMMPRIN mRNA levels were significantly higher
in grade IV than grade III (p = 0.0005) primary astrocytomas patient
samples and non-tumor controls (p = 0.00001). b, c By immunostain
score, EMMPRIN positively correlated with WHO grades in human
astrocytomas (p = 0.008), and meningiomas (p = 0.048, by Pearson
product method correlation test), respectively. Representative hema-
toxylin and eosin staining of d glioblastomas multiforme, e anaplastic
astrocytomas, f diffuse astrocytomas, and g pilocytic astrocytomas.
Immuno-histochemical staining of EMMPRIN in h glioblastomas
multiforme, i anaplastic astrocytomas, j diffuse astrocytomas, and
k pilocytic astrocytomas. Representative hematoxylin and eosin
staining of l anaplastic, m atypical, n meningothelial meningiomas,
and o non-neoplastic brain tissues. Immuno-histochemical staining of
EMMPRIN in p anaplastic, q atypical, r meningothelial meningio-
mas, and s non-neoplastic brain tissues. Original magnification 9400
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In vitro validation using GEO bioinformatics analysis
of the EMMPRIN mRNA expression in glioma cell
lines
Using the GDS3885 database, the EMMPRIN mRNA
expression in conventional glioma cell lines, glioma pri-
mary culture cells, and glioma stem-like cells were ana-
lyzed. There was no significant difference among
conventional glioma cell lines (n = 36), glioma primary
culture cells (n = 27), and glioblastoma stem-like cells
(n = 12) from human primary brain gliomas (Fig. 2a–c).
This suggests that glioma cell lines recapitulate transcrip-
tional features of gliomas, thereby allowing the investiga-
tion of therapeutic candidates.
Serial passages on alterations of EMMPRIN, EST1,
and p16 mRNA expression profiles
Regarding the GDS3885 database, eight pairs of serial
passages data were achieved from the early and late pas-
sages of glioma stem-like cells. EMMPRIN mRNA
expression decreased in six of the eight pairs (75 %),
including GS-1, GS-3, GS-5, GS-7, GS-8, and GS-9 when
comparing the early with the late passages (Fig. 2d). Since
serial passage decreased the amount and length of telo-
meric DNA in human fibroblasts [33], the mRNA
expression of telomere-regulated genes was further
checked. Ever shorter telomeres protein 1 (EST1) [34] was
one of the telomere-regulated sub-units directly involved in
telomere replication and correlated with telomerase.
Analyses of EST1 showed higher EST1 in early passage
than in late passage (Fig. 2e). Since the reduction of telo-
mere length led to senescence, the p16 belonged to the
senescence-regulated gene [35]. Further investigation of
the mRNA expression of p16 revealed that later passage
expressed higher level of p16 than early passage in four of
six glioma stem-like cells, including GS-3, GS-5, GS-8,
and GS-9 (Fig. 2f), suggesting the serial passage-induced
senescence of gliomas.
In vitro validation using Western blot analysis
confirmed the overexpression of EMMPRIN in glioma
cells
To determine the EMMPRIN protein production in human
glioma cell line, Western blots showed that EMMPRIN
protein production was overexpressed in human glioma
cell lines (Fig. 3a) and was higher in GBM8401 than in
U87MG, or LN229 glioma cell lines. The high EMMPRIN-
expressing GBM8401 was then used for further xenograft
study.















Non-neoplastic brain tissueb 3 0.3 ± 0.2 0.5 ± 0.3 0.5 ± 0.4
WHO grades of astrocytomas
Pilocytic astrocytoma, WHO
grade I




10 1.1 ± 0.8 1.4 ± 0.5 2.0 ± 1.3
Anaplastic astrocytomas, WHO
grade III
9 2.6 ± 1.3 2.8 ± 1.1 7.3 ± 3.0
Glioblastoma multiforme WHO
grade IV
18 2.5 ± 1.2 3.1 ± 0.9 7.8 ± 2.1
WHO grades of meningiomas
Meningiomas, WHO grade I 41 0.8 ± 0.4 1.2 ± 0.5 1.3 ± 0.6 Positive correlation
(p = 0.048*)Atypical meningiomas, WHO
grade II
12 1.8 ± 0.8 2.9 ± 1.2 5.0 ± 1.8
Anaplastic meningiomas, WHO
grade III
6 2.1 ± 1.4 3.1 ± 1.4 6.6 ± 3.1
EMMPRIN Extracellular matrix metalloproteinase inducer, WHO World Health Organization
* Means statistical significance
a The correlation was analyzed by Pearson Product Method Correlation test
b These three non-neoplastic brain tissues were taken from non-tumor part of diffuse astrocytomas (WHO grade II)
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Immunohistochemical and immunofluorescence
staining of xenograft confirmed EMMPRIN
overexpression in high-grade astrocytomas
The GBM8401-xenograft formed glioma mass in the right
hemisphere, with invasive glioma tumor islands (Fig. 3b,
c) after 2-week inoculation. The high EMMPRIN-
expressing glioma cells also displayed a highly invasive
phenotype, with invasive glioma islands growing away
from the original xenograft site (Fig. 3d). In contrast, the
normal control of astrocytes and endothelial cells showed
low-EMMPRIN expression, while oligodendrocytes were
negative for EMMPRIN staining (Fig. 3e–g). The high
EMMPRIN-expressing glioma cells were further identified
via IF staining with antibodies specific for EMMPRIN. The
FITC-labeled EMMPRIN-expressing GBM8401 glioma
cells were distributed near the invasive front at the tumor–
brain interface with some invasive tumor islands away
from the glioma main tumor mass, compared to the con-
tralateral normal control of brain astrocytes that showed
only faint FITC fluorescence (Fig. 3h–m). Based on these
evidences, high-grade brain tumors overexpressed
EMMPRIN.
Relationships of EMMPRIN mRNA to survival of high-
grade astrocytomas
Using the GDS1962 database, survival analysis was
achieved from 77 public delinked databases. The median
survival time in patients with WHO grade III and grade IV
astrocytomas was 175 and 71.5 weeks, respectively. Kap-
lan–Meier post-operative survival analysis was applied to
investigate the relationship between overall survival of
patients with high grade astrocytomas and EMMPRIN
mRNA levels. Overall survival was poor in patients with
WHO grade IV (n = 56) than WHO grade III astrocytomas
Fig. 2 Comparison of the EMMPRIN mRNA expressions among
a conventional astrocytoma cell lines (n = 36), b glioblastoma stem-
like cells (n = 27), and c astrocytoma primary culture cells (n = 12)
from GDS3885 dataset of GEO profile. Glioma cell lines recapitu-
lated the transcriptional value of EMMPRIN in the above three types
of glioma cells. d–f Alterations of EMMPRIN, EST1, and p16 mRNA
expressions after serial passages. The mRNA expression in serial
passages of glioma-stem like cells showed decreased EMMPRIN and
EST1, but increased p16 when comparing early to late passages
286 J Neurooncol (2013) 114:281–290
123
Fig. 3 Western blot analysis of astrocytomas cell lines, and histo-
pathologic staining of EMMPRIN-expressing in GBM8401 glioma
xenografts. a Western blot analysis of EMMPRIN expression in
GBM8401, U87MG, LN229 glioma cells, and positive control HepG2
hepatoma cell line. EMMPRIN protein production consisted of HG
high glycosylation, and LG low glycosylation forms. The expression
of a-actin was used as internal control. Hematoxylin and eosin
staining of GBM8401 glioma xenograft in b coronal section of the
brain and c tumor–brain interface. d Immuno-histochemical staining
revealed EMMPRIN-expressing invasive tumor islands (black
arrows). e–g The normal control of astrocytes (black arrows),
oligodendrocytes (white arrows), and endothelial cells (black arrow
head). In the immuno-fluorescence staining with antibodies specific
for EMMPRIN, h FITC-labeled EMMPRIN-expressing GBM8401
glioma cells were distributed near the invasive front at the tumor–
brain interface (dash line) with some invasive tumor islands away
from the main tumor mass. k The contralateral normal control of
brain astrocytes showed only faint FITC fluorescence. i, l DAPI-
stained nuclei. j, m The merged photos of FITC-labeled EMMPRIN
expressing tumors and DAPI-stained nuclei. Original magnification
9100. Data were representative of three independent experiments.
T tumor, N neighborhood brain parenchyma. Original magnification
912.5 (b); 9200 (c, d); 91,000 in (e–g); and 9100 (h–m). (Color
figure online)
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(n = 21) (p = 0.0001, by log-rank test; 95 % CI:
1.842–3.053) (Fig. 4a). This result consistently indicated
that the GDS1962 database was a reliable positive control
for survival analysis.
The cut-off value was then set up at 1,500, or the point
of median EMMPRIN gene expression value. The median
survival time of patients with low and high EMMPRIN
expressions was 97 and 90.5 weeks, respectively. Patients
with high-grade astrocytomas and high EMMPRIN mRNA
levels (n = 36) did not have worse overall survival than
patients with low EMMPRIN mRNA expression (n = 41)
(p = 0.7274, by log-rank test; 95 % CI: 0.4327–1.711)
(Fig. 4b). Kaplan–Meier post-operative survival analysis
did not show any statistical significance when the cut-off
value of EMMPRIN expression was set to low (\1,000,
n = 19), intermediate (1,000–2,000, n = 39), and high
([2,000, n = 19) (Fig. 4c).
Discussion
This study validates a simple strategy using GEO bioin-
formatics and wet lab approaches to identify the biomarker,
EMMPRIN, in human brain tumors. Li et al. [36] investi-
gated EMMPRIN (also known as CD147) mRNA expres-
sion and IHC in 50 cases and found that EMMPRIN
expression levels were apparently elevated in high-grade
astrocytomas. This was consistent with the finding of the
present study. Their study also found that higher expression
of EMMPRIN was associated with poor survival time in
their astrocytoma patient cohort. In contrast, regarding the
stratification of EMMPRIN gene expression level, Kaplan–
Meier survival analysis of the GDS1815 database showed
no statistical difference in 77 primary high grade astrocy-
tomas, suggesting that EMMPRIN was not the only factor
that played a role in determining outcome. Other factors,
such as nodal and osteopontin, are also important
contributors to invasiveness and survival in astrocytomas
[25, 30, 32]. The other possible explanations include the
limitation of patient populations that only involved high-
grade, but not low-grade, controls.
Complete resections of meningiomas and tumor bed
meninges have the advantage of reducing recurrence in
benign or atypical meningiomas, but the results are not
satisfactory [37]. This suggests that there are still other
molecular factors like EMMPRIN and MMPs aiding tumor
cell invasion to move away from the main tumor mass and
infiltrate the normal brain parenchyma, leading to tumor
recurrence.
The paradigm of tumor stem-like cells has been estab-
lished in human astrocytomas [31] and meningiomas [38–
41]. Human glioma cells exhibit radio-resistance and
higher colony formation ability in CD133-expressed gli-
oma sub-populations [31]. Consistently, human meningi-
oma stem-like cells display chemotherapeutic resistance,
radiation resistance, high tumorigenicity, and infiltration
into the surrounding normal brain parenchyma [40]. One of
the interesting findings is the trend of EMMPRIN mRNA
expression decreasing in 75 % of serial passages of glioma
stem-like cells. It has been reported that in vitro serial
passage decreases the amount and length of telomeric DNA
in human fibroblasts [33]. Further analyzing EST1, one of
the telomere-regulated sub-units, showed that early passage
display higher EST1 than late passage, consistent with the
serial passage effect. Other possible reasons include
senescence. Investigation of p16 revealed that later passage
expressed higher p16 level than early passage in 75 % of
glioma stem-like cells, suggesting the serial passage-
induced senescence of gliomas. Overexpression of p16
induces senescence and cell cycle arrest to suppress the
invasion and proliferation of human glioma cell lines
U87MG and U373 MG. The p16-overexpressed glioma
cells are positive for senescence-associated beta-galacto-
sidase staining and enlarged morphology [35].
Fig. 4 Kaplan-Meier survival analyses of high grade astrocytomas.
a Survival patterns in patients with WHO grade IV (n = 56)
compared to those with WHO grade III (n = 21) high-grade
astrocytomas (p = 0.0001, by log-rank test). b Patterns of patients
with high EMMPRIN ([1,500, n = 36) versus low EMMPRIN
(\1,500, n = 41) expressions (p = 0.7274, by log-rank test). c Pat-
terns of patients with high EMMPRIN ([2,000, n = 19) versus
intermediate high (n = 39) and low EMMPRIN (\1,000, n = 19)
expressions (p = 0.6981, by log-rank test)
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It is difficult to obtain the hundred number scales of
fresh or frozen samples from human brain tumors, espe-
cially for low-grade astrocytomas, to analyze the mRNA
expression or protein level. Instead, using the GEO profile
provides an enormous public delinked database for the
investigation of molecular cell biology of human brain
astrocytomas [5, 25]. However, there are still some limi-
tations inherent to this study. One database alone cannot
provide all the information at the same time for investi-
gating mRNA gene expression, protein level, survival time,
and clinico-pathologic parameters. To overcome this,
multiple databases, including GDS1962, GDS3885, and
GDS1815, were used. In meningiomas, limited by the tis-
sue sample amount and GEO database source, the mRNA
expression, survival, and cell line data were not obtained in
this study. Instead, tissue microarray-based immuno-his-
tochemical staining provided immuno-staining score for
study of meningioma samples. Sufficient human meningi-
oma samples in future studies are warranted to allow
extensive studies of EMMPRIN.
Conclusions
This study demonstrates a simple strategy of using GEO
bioinformatics and wet lab approaches to identify potential
biomarkers in human brain tumors. High-grade brain
tumors overexpress EMMPRIN and EMMPRIN expression
positively correlates with WHO grades in human astrocy-
tomas and meningiomas, suggesting that EMMPRIN may
be a therapeutic target of brain tumor. Future genetic-
modified tumor cell manipulation, such as silencing
EMMPRIN, may identify the role of EMMPRIN in mod-
ulating invasiveness and the underlying signaling pathway.
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